These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 32112040)

  • 1. Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson's disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin.
    Guo CH; Cao T; Zheng LT; Waddington JL; Zhen XC
    Acta Pharmacol Sin; 2020 Apr; 41(4):499-507. PubMed ID: 32112040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nei-like 1 inhibition results in motor dysfunction and promotes inflammation in Parkinson's disease mice model.
    Xue B; Xiao W; Tian H
    Biochem Biophys Res Commun; 2020 Jan; 521(1):245-251. PubMed ID: 31653343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
    Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JNK-mediated microglial DICER degradation potentiates inflammatory responses to induce dopaminergic neuron loss.
    Wang Q; He Q; Chen Y; Shao W; Yuan C; Wang Y
    J Neuroinflammation; 2018 Jun; 15(1):184. PubMed ID: 29907159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson's disease by suppressing glycogen synthase kinase-3 beta activity.
    Ren ZX; Zhao YF; Cao T; Zhen XC
    Acta Pharmacol Sin; 2016 Sep; 37(10):1315-1324. PubMed ID: 27374489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
    Urs NM; Bido S; Peterson SM; Daigle TL; Bass CE; Gainetdinov RR; Bezard E; Caron MG
    Proc Natl Acad Sci U S A; 2015 May; 112(19):E2517-26. PubMed ID: 25918399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel fatty acid-binding protein 3 ligand inhibits dopaminergic neuronal death and improves motor and cognitive impairments in Parkinson's disease model mice.
    Haga H; Yamada R; Izumi H; Shinoda Y; Kawahata I; Miyachi H; Fukunaga K
    Pharmacol Biochem Behav; 2020 Apr; 191():172891. PubMed ID: 32126223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chaperone Sigma1R mediates the neuroprotective action of afobazole in the 6-OHDA model of Parkinson's disease.
    Voronin MV; Kadnikov IA; Voronkov DN; Seredenin SB
    Sci Rep; 2019 Nov; 9(1):17020. PubMed ID: 31745133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease.
    Costantini LC; Cole D; Chaturvedi P; Isacson O
    Eur J Neurosci; 2001 Mar; 13(6):1085-92. PubMed ID: 11285005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease.
    Spathis AD; Asvos X; Ziavra D; Karampelas T; Topouzis S; Cournia Z; Qing X; Alexakos P; Smits LM; Dalla C; Rideout HJ; Schwamborn JC; Tamvakopoulos C; Fokas D; Vassilatis DK
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3999-4004. PubMed ID: 28348207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-apoptotic effect of modified Chunsimyeolda-tang, a traditional Korean herbal formula, on MPTP-induced neuronal cell death in a Parkinson's disease mouse model.
    Li H; Park G; Bae N; Kim J; Oh MS; Yang HO
    J Ethnopharmacol; 2015 Dec; 176():336-44. PubMed ID: 26593210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E; Rogers JT; Devoto P; Björklund A; Carta M
    Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dicer and microRNAs protect adult dopamine neurons.
    Chmielarz P; Konovalova J; Najam SS; Alter H; Piepponen TP; Erfle H; Sonntag KC; Schütz G; Vinnikov IA; Domanskyi A
    Cell Death Dis; 2017 May; 8(5):e2813. PubMed ID: 28542144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.
    Kasture S; Pontis S; Pinna A; Schintu N; Spina L; Longoni R; Simola N; Ballero M; Morelli M
    Neurotox Res; 2009 Feb; 15(2):111-22. PubMed ID: 19384573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
    Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
    Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
    Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
    J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.
    Bazzu G; Calia G; Puggioni G; Spissu Y; Rocchitta G; Debetto P; Grigoletto J; Zusso M; Migheli R; Serra PA; Desole MS; Miele E
    CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):482-90. PubMed ID: 20522009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.